By Chris McSpiritt, Senior Director, Clinical Strategy, Veeva Systems
This is part one in a series about how collaboration can impact TMF quality and inspection readiness.
In the race for a COVID vaccine, we’re seeing amazing collaboration between the private sector, government, and academic research. Collaboration can become a force multiplier for speed and impact, leading to greater productivity, increased efficiency, and better outcomes.
If collaboration isn’t the heart of your solution, your organization will struggle as the trial landscape becomes increasingly complex. Pharma companies are spending more and more on partners and CROs. In fact, some sponsors are hiring multiple CROs to handle individual functions, such as one to execute the trial, one to monitor the trial, one for data management, one for feasibility and startup, etc. With so many hands in the cookie jar, driving collaboration among the increasing number of actors is critical to successfully conducting the study and maintaining the TMF properly.